New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer
BD (NYSE: BDX) has released a concerning survey about women's gynecological health practices. The Harris Poll survey, conducted in November 2024 among 1,100+ U.S. women, revealed that 72% have delayed gynecology visits, with 54% citing fear or discomfort and 49% mentioning scheduling challenges.
Key findings include: 50% of women are uncertain about cervical cancer screening frequency; 81% desire more comfortable testing options; and 73% show interest in self-collection methods at doctor's offices. Despite 66% claiming knowledge about HPV, 88% are unaware that Pap tests aren't the most accurate for detecting cervical cancer.
The company's BD Onclarity™ HPV Assay, FDA-approved for self-collection, identifies more high-risk HPV types than other tests. Major health organizations, including WHO and ACS, now recommend self-collection for HPV screening. WHO aims to eliminate cervical cancer as a public health issue by 2030, noting it's currently the fourth most common cancer in women worldwide.
BD (NYSE: BDX) ha pubblicato un preoccupante sondaggio sulle pratiche di salute ginecologica delle donne. Il sondaggio condotto da Harris Poll nel novembre 2024 tra oltre 1.100 donne statunitensi ha rivelato che il 72% ha ritardato le visite ginecologiche, con il 54% che cita paura o disagio e il 49% che menziona difficoltà di programmazione.
I principali risultati includono: il 50% delle donne è incerto sulla frequenza degli screening per il cancro cervicale; l'81% desidera opzioni di test più confortevoli; e il 73% mostra interesse per metodi di auto-raccolta presso gli studi medici. Nonostante il 66% affermi di avere conoscenza dell'HPV, l'88% non è a conoscenza del fatto che i test di Pap non sono i più accurati per rilevare il cancro cervicale.
Il BD Onclarity™ HPV Assay dell'azienda, approvato dalla FDA per l'auto-raccolta, identifica più tipi di HPV ad alto rischio rispetto ad altri test. Le principali organizzazioni sanitarie, tra cui l'OMS e l'ACS, ora raccomandano l'auto-raccolta per lo screening dell'HPV. L'OMS punta ad eliminare il cancro cervicale come problema di salute pubblica entro il 2030, evidenziando che attualmente è il quarto cancro più comune tra le donne nel mondo.
BD (NYSE: BDX) ha publicado una encuesta preocupante sobre las prácticas de salud ginecológica de las mujeres. La encuesta de Harris Poll, realizada en noviembre de 2024 entre más de 1.100 mujeres de EE. UU., reveló que el 72% ha retrasado las visitas ginecológicas, siendo el 54% por miedo o incomodidad y el 49% por dificultades para programar.
Los hallazgos clave incluyen: el 50% de las mujeres no está seguro sobre la frecuencia del cribado de cáncer de cuello uterino; el 81% desea opciones de pruebas más cómodas; y el 73% muestra interés en métodos de auto-recolección en los consultorios médicos. A pesar de que el 66% afirma conocer el HPV, el 88% desconoce que las pruebas de Papanicolaou no son las más precisas para detectar el cáncer de cuello uterino.
La BD Onclarity™ HPV Assay de la compañía, aprobada por la FDA para auto-recolección, identifica más tipos de HPV de alto riesgo que otras pruebas. Las principales organizaciones de salud, incluyendo la OMS y la ACS, ahora recomiendan la auto-recolección para la detección de HPV. La OMS tiene como objetivo eliminar el cáncer cervical como un problema de salud pública para 2030, señalando que actualmente es el cuarto cáncer más común en mujeres en todo el mundo.
BD (NYSE: BDX)는 여성의 부인과 건강 관행에 대한 우려되는 설문조사를 발표했습니다. 2024년 11월에 1,100명 이상의 미국 여성들을 대상으로 진행된 Harris Poll 설문조사에 따르면, 72%가 부인과 진료를 미뤘습니다, 그중 54%는 두려움이나 불편함을 이유로, 49%는 Scheduling 문제를 언급했습니다.
주요 발견 사항은: 여성의 50%가 자궁경부암 검진 주기에 확신이 없다; 81%는 더 편안한 검사 옵션을 원하고; 73%는 의원에서의 자가 채취 방법에 관심을 보입니다. 66%는 HPV에 대한 지식이 있다고 주장하지만, 88%는 유세포검사가 자궁경부암을 탐지하는 데 가장 정확하지 않다는 사실을 모르고 있습니다.
회사의 BD Onclarity™ HPV Assay는 자가 채취를 위해 FDA의 승인을 받았으며, 다른 테스트보다 더 많은 고위험 HPV 유형을 식별합니다. WHO와 ACS를 포함한 주요 보건 기관들은 현재 HPV 검진을 위한 자가 채취를 권장합니다. WHO는 2030년까지 자궁경부암을 공공 건강 문제로 없애겠다는 목표를 세우고 있으며, 현재 전 세계 여성에게 넷째로 흔한 암이라고 언급하고 있습니다.
BD (NYSE: BDX) a publié une enquête préoccupante sur les pratiques de santé gynécologique des femmes. L'enquête Harris Poll, réalisée en novembre 2024 auprès de plus de 1 100 femmes américaines, a révélé que 72 % ont retardé leurs visites chez le gynécologue, dont 54 % en raison de la peur ou de l'inconfort et 49 % mentionnant des difficultés de prise de rendez-vous.
Les résultats clés incluent : 50 % des femmes ne sont pas certaines de la fréquence du dépistage du cancer du col de l'utérus; 81 % souhaitent des options de test plus confortables; et 73 % montrent de l'intérêt pour des méthodes d'auto-collecte dans les cabinets médicaux. Bien que 66 % affirment connaître l'HPV, 88 % ignorent que les tests de Pap ne sont pas les plus précis pour détecter le cancer du col de l'utérus.
Le BD Onclarity™ HPV Assay de l'entreprise, approuvé par la FDA pour l'auto-collecte, identifie plus de types de HPV à haut risque que d'autres tests. Les principales organisations de santé, y compris l'OMS et l'ACS, recommandent désormais l'auto-collecte pour le dépistage de l'HPV. L'OMS vise à éliminer le cancer du col de l'utérus en tant que problème de santé publique d'ici 2030, notant qu'il est actuellement le quatrième cancer le plus courant chez les femmes dans le monde.
BD (NYSE: BDX) hat eine besorgniserregende Umfrage über die gynäkologischen Gesundheitspraktiken von Frauen veröffentlicht. Die Harris Poll Umfrage, die im November 2024 unter mehr als 1.100 US-Frauen durchgeführt wurde, ergab, dass 72% der Befragten gynäkologische Untersuchungen verzögert haben, wobei 54% Angst oder Unbehagen und 49% Planungsprobleme angaben.
Wichtige Ergebnisse sind: 50% der Frauen sind unsicher über die Häufigkeit der Gebärmutterhalskrebsuntersuchungen; 81% wünschen sich angenehmere Testoptionen; und 73% interessieren sich für Selbstentnahmemethoden in Arztpraxen. Trotz 66%, die behaupten, über HPV informiert zu sein, sind 88% nicht bewusst, dass Pap-Tests nicht die genauesten zur Erkennung von Gebärmutterhalskrebs sind.
Der BD Onclarity™ HPV Assay des Unternehmens, der von der FDA für die Selbstentnahme genehmigt wurde, identifiziert mehr Hochrisiko-HPV-Typen als andere Tests. Große Gesundheitsorganisationen, darunter die WHO und die ACS, empfehlen jetzt die Selbstentnahme für HPV-Screenings. Die WHO hat das Ziel, Gebärmutterhalskrebs bis 2030 als öffentliches Gesundheitsproblem zu eliminieren, wobei derzeit auf den vierten Platz unter den häufigsten Krebserkrankungen bei Frauen weltweit verwiesen wird.
- None.
- None.
Women Are Seeking More Convenience and Less Discomfort in Testing Options
FRANKLIN LAKES, N.J., Jan. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new survey, revealing that
According to the survey, conducted online by The Harris Poll among over 1,100 adult women in the
"The fact that women are skipping this potentially life-saving screening due to fear or scheduling makes it clear that the health industry needs to make the process more comfortable and convenient," said Dr. Jeff Andrews, a board-certified OB/GYN physician and vice president, Medical Affairs at BD. "Self-collection of vaginal samples reduces both the discomfort and time associated with a pelvic exam and is a critical step forward in cervical cancer screening."
Desire for Better Testing Options
The new study found that
The survey found that while
"Medical research continues to be focused on the worthy goal of finding 'a cure for cancer,' but we're already able to help prevent cervical cancer today," said Nikos Pavlidis, worldwide president of BD Diagnostic Solutions. "The combination of vaccines, more precise HPV tests and self-collection will be important factors as we work to eliminate cervical cancer as a public health risk."
The BD Onclarity™ HPV Assay is FDA-approved for self-collection, and it also identifies more individual high-risk types or strains of HPV than any other test. Being able to identify more individual types of HPV means that clinicians can track those types across a patient's visits to more effectively manage high-risk cases and better guide follow-up for low-risk patients. This targeted approach helps ensure that women and people with a cervix receive the most appropriate care for their situation and avoid return visits to the doctor's office for invasive tests that may not be necessary.
Guidelines from a growing number of national and international agencies, including the World Health Organization (WHO), the American Cancer Society (ACS), the American Society for Coloscopy and Cervical Pathology (ASCCP) and the
According to the WHO, a woman dies of cervical cancer every two minutes. Cervical cancer is the fourth most common cancer in women worldwide, both in terms of incidence and deaths, but it is preventable with regular screening. The WHO aims to eliminate cervical cancer as a public health issue by 2030.
This survey was conducted online within
For the complete research method and additional survey results, please contact mela.sera@bd.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson
Contacts: | |
Media | Investors |
Mela Sera, APR | Adam Reiffe Sr. Director, Investor Relations 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-survey-finds-women-are-skipping-their-obgyn-exams-increasing-risks-for-cervical-cancer-302346535.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What percentage of women are delaying gynecological visits according to BD's 2024 survey?
How many women are interested in self-collection HPV testing according to BDX's latest study?
What are the main reasons women skip gynecological exams according to BD's research?
How does BD's Onclarity HPV Assay differ from other HPV tests?
What percentage of women understand cervical cancer screening guidelines according to BDX's survey?
What is WHO's target date for eliminating cervical cancer as a public health issue?
